Jump to content

Ajanta Pharma: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
removed third-party hatnote
m Clean up spacing around commas and other punctuation fixes, replaced: , → , (2), ; → ; (3)
 
(46 intermediate revisions by 29 users not shown)
Line 1: Line 1:
{{short description|Indian pharmaceutical company established in 1973}}
{{Multiple issues|
{{COI|date=January 2019}}
{{COI|date=January 2019}}
{{Advert|date=March 2020}}
{{More citations needed|date=March 2020}}
}}
{{EngvarB|date=February 2016}}
{{EngvarB|date=February 2016}}
{{Use dmy dates|date=February 2016}}
{{Use dmy dates|date=February 2016}}
{{infobox company
{{infobox company
| name = Ajanta Pharma Limited
| name = Ajanta Pharma Limited
| logo = Ajanta logo.gif
| logo = Ajanta logo.png
| type = Public Company
| type = Public Company
| traded_as = {{ubl|{{BSE|532331}}|{{NSE|AJANTPHARM}}}}
| traded_as = {{ubl|{{BSE|532331}}|{{NSE|AJANTPHARM}}}}
Line 11: Line 16:
| founder =
| founder =
| defunct =
| defunct =
| website = http://www.ajantapharma.com/
| fate =
| area_served =
| area_served =
| key_people = Yogesh Agrawal, Managing Director.
| key_people = Yogesh Agrawal, Managing Director.
Line 18: Line 23:
| products = Branded Generic Formulations / Medicines
| products = Branded Generic Formulations / Medicines
| services =
| services =
| revenue = {{profit}} {{INRConvert|2155|C}} (2017–2018)
| revenue = {{profit}} {{INRConvert|2916|C}} (2020–2021)
| operating_income =
| operating_income =
| net_income =
| net_income =
Line 25: Line 30:
| equity =
| equity =
| owner =
| owner =
| num_employees = 6,500+
| num_employees = 7,000+
| parent =
| parent =
| divisions =
| divisions =
| subsid = {{unbulleted list |Ajanta Pharma (Mauritius) Ltd |Ajanta Pharma Philippines Inc. |Ajanta Pharma USA Inc.<ref name="TriFid Research 2016" /> |Ajanta Pharma Nigeria Ltd.<ref name="Ajanta Our Business" /> }}
| subsid = {{unbulleted list |Ajanta Pharma (Mauritius) Ltd |Ajanta Pharma Philippines Inc. |Ajanta Pharma USA Inc.<ref name="TriFid Research 2016" /> |Ajanta Pharma Nigeria Ltd.<ref name="Ajanta Our Business" /> }}
| footnotes = <ref name="Ajanta Contact Us">{{cite web|url=http://ajantapharma.com/ContactUs_India.aspx |title=Welcome To Ajanta Pharma |publisher=Ajantapharma.com |accessdate=29 February 2016}}{{self-published source|date=December 2019}}</ref>; <ref name="TriFid Research 2016">{{cite magazine |magazine=Daily Market Insights |url=https://archive.org/details/WelcomeToTrifidResearchStockTips/page/n2 |via=Internet Archive |title=Stock Snippets |date=15 June 2016 |publisher=TriFid Research |page=2 |quote=Ajanta Pharma announced the launch of anti-dementia Memantine Hydrochloride tablets in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc.}}</ref>;<ref name="Ajanta Our Business">{{cite web|url=http://ajantapharma.com/branded-generics.html |title=Ajanta Pharma Limited - Our Business |publisher=Company |accessdate=29 February 2016}}{{Self-published source|date=December 2019}}</ref>
| footnotes = ;<ref name="Ajanta Contact Us">{{cite web|url=http://ajantapharma.com/ContactUs_India.aspx |title=Welcome To Ajanta Pharma |publisher=Ajantapharma.com |access-date=29 February 2016}}{{self-published source|date=December 2019}}</ref><ref name="TriFid Research 2016">{{cite magazine |magazine=Daily Market Insights |url=https://archive.org/details/WelcomeToTrifidResearchStockTips/page/n2 |via=Internet Archive |title=Stock Snippets |date=15 June 2016 |publisher=TriFid Research |page=2 |quote=Ajanta Pharma announced the launch of anti-dementia Memantine Hydrochloride tablets in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc.}}</ref><ref name="Ajanta Our Business">{{cite web|url=http://ajantapharma.com/branded-generics.html |title=Ajanta Pharma Limited - Our Business |publisher=Company |access-date=29 February 2016}}{{Self-published source|date=December 2019}}</ref>
| caption =
| caption =
| location_city = [[Mumbai]], [[Maharashtra]]<ref name="Ajanta Contact Us" />
| location_city = [[Mumbai]], [[Maharashtra]]<ref name="Ajanta Contact Us" />
| location_country = India
| location_country = India
| locations =
| locations =
| foundation = 1973
| foundation = 1973, 51 years
}}
}}


'''Ajanta Pharma Limited''' (APL) is an multinational company based in India engaged in development, manufacturing, and marketing of pharmaceutical formulations. It has a presence in India, the United States, and about 30 other countries in Africa, Asia, Middle East, and CIS. It was established in 1973.
'''Ajanta Pharma Limited''', also known by the [[acronym]] APL, is a multinational company based in [[India]] engaged in development, manufacturing, and marketing of pharmaceutical formulations. It has a presence in India, the [[United States]], and about 30 other countries in [[Africa]], [[South East Asia]], [[West Asia]], and [[Commonwealth of Independent States|CIS]]. It was established in 1973.


==Markets and business==
==Markets and business==
Ajanta Pharma has over 1,400 products registered currently in various countries and equal number of products are under approval. In India, the company is a branded generic company focused on a few high growth specialty therapies in ophthalmology, dermatology, cardiology, and pain management.
Ajanta Pharma has over 1,400 products registered currently in various countries and an equal number of products are under approval. In India, the company is a branded generic company focused on a few high growth specialty therapies in ophthalmology, dermatology, cardiology, and pain management.


Ajanta Pharma exports products to over 30 countries in Asia and Africa. In these markets, the company serves a wide range of therapeutic products in the areas of antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology, and pain management.
Ajanta Pharma exports products to over 30 countries in Asia and Africa. In these markets, the company serves a wide range of therapeutic products in the areas of antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology, and pain management.


Ajanta Pharma has recently stepped up its presence in the United States with a select product portfolio, which includes niche and complex technology products. Currently, the company has 27 products in the US market.<ref>http://www.ajantapharma.com/AdminData/Results/Q3FY2019PressReleaseandResults.pdf</ref>
Ajanta Pharma has recently stepped up its presence in the United States with a select product portfolio, which includes niche and complex technology products. Currently, the company has 27 products in the US market.<ref>{{cite press release |title=Profit After Tax at 14% of Revenue (3rd Quarter & 9 Months, FY 2019 Consolidated Results) |url=http://www.ajantapharma.com/AdminData/Results/Q3FY2019PressReleaseandResults.pdf |publisher=Ajanta Pharma Limited |archive-url=https://web.archive.org/web/20200927061536/http://www.ajantapharma.com/AdminData/Results/Q3FY2019PressReleaseandResults.pdf |archive-date=27 September 2020 |url-status=dead}}</ref>


=== History ===
=== History ===
In the early 2000s, Ajanta was noted as a major source of foreign currency, alongside [[Dr. Reddy's Laboratories|Reddy Labs]], arising from sales in Southeast Asia.<ref name="Lal 2006" /> In particular, in 2003, a joint-venture between Ajanta and the [[Ministry of Health (Turkmenistan)|Ministry of Health in Turkministan]] accounted for fully half of the pharmaceutical needs of the country.<ref name="Lal 2006" />
In the early 2000s, Ajanta was noted as a major source of foreign currency, alongside [[Dr. Reddy's Laboratories|Reddy Labs]], arising from sales in Southeast Asia.<ref name="Lal 2006" /> In particular, in 2003, a joint-venture between Ajanta and the [[Ministry of Health (Turkmenistan)|Ministry of Health in Turkmenistan]] accounted for fully half of the pharmaceutical needs of the country.<ref name="Lal 2006" /> The company had made several other joint-ventures with regional governments, such as [[Uzbekistan]], [[Kazakhstan]], [[Kyrgyzstan|Kyrygyzstan]] and [[Tajikistan]], which it severed in the 2010s due to their being unprofitable.<ref>{{Cite report|url=https://archive.org/details/05NEWDELHI7494/page/n1|title=GOI Considering Russian Thrust in Central Asia|date=26 September 2015|publisher=United States Department of State|page=2|access-date=8 Dec 2019|via=Internet Archive|type=Partial extract from original diplomatic, classified cable}}</ref>


The company experienced an enormous loss in 2005<ref group="nt">Year ending 31 March 2005</ref> in terms of diminution of the value of investments, amounting to four-times the year's profits.<ref name="Accounting and Analysis 2006" /> That same year, the company was noted as having the highest sales in India for any Indian pharmaceutical company, with sales of ₹13.56 billion.<ref name="Thukral 2016" />
The company experienced an enormous loss in 2005<ref group="nt">Year ending 31 March 2005</ref> in terms of diminution of the value of investments, amounting to four times the year's profits.<ref name="Accounting and Analysis 2006" /> That same year, the company was noted as having the highest sales in India for any Indian pharmaceutical company, with sales of ₹13.56 billion.<ref name="Thukral 2016" />

In 2015, the company was highlighted as having had exceptional stock appreciation over the preceding four years, and the listing of the stock on the [[BSE 500]] was noted.<ref>{{Cite magazine|last=Oberoi|first=Rahul|date=April 2015|title=Bullish Moves: We discuss three ratios that can help identify good stocks|url=https://archive.org/details/Money_Today_April_2015_IN/page/n50|magazine=Money Today|location=New Delhi, India|publisher=India Today Group|volume=10|issue=4|page=49|via=Internet Archive}}</ref> By 2019, the stock was listed on the S&P BSE 200 index.<ref>{{Cite web|url=https://www.bseindia.com/stock-share-price/ajanta-pharma-ltd/ajantpharm/532331/|title=Ajanta Pharma Ltd Live Stock Price, Ajantpharm Live Share Price, 532331|date=8 December 2019|website=BSE|url-status=live|archive-url=https://archive.today/20191209033240/https://www.bseindia.com/stock-share-price/ajanta-pharma-ltd/ajantpharm/532331/|archive-date=9 December 2019|access-date=8 Dec 2019}}</ref>


==Manufacturing facilities==
==Manufacturing facilities==
Ajanta Pharma operates seven manufacturing facilities; six within India and one in Mauritius. In India, five facilities manufacture finished formulations, including Dahej and Paithan plants which is approved by US FDA and Guwahati plant which caters to domestic and emerging markets. Another plant manufactures [[active pharmaceutical ingredient]]s (APIs) primarily for captive consumption.
Ajanta Pharma operates seven manufacturing facilities in India. Six facilities manufacture finished formulations, including Dahej and Paithan plants which is approved by the US FDA and [[Guwahati]] plant which caters to domestic and emerging markets. Another plant manufactures [[active pharmaceutical ingredient]]s (APIs) primarily for captive consumption.


== Legal proceedings ==
== Legal proceedings ==
[[Bayer]]<ref group="nt">Specifically Bayer Intellectual Property GMBH</ref> filed suit before the [[Delhi High Court]] accusing Ajanta of [[patent infringement]] on the [[erectile dysfunction]] treatments [[vardenafil]] and [[vardenafil hydrochloride]].<ref name="Bayer vs Ajanta" /> Ajanti argued that Bayer was not using it's patent in India for the benefit of India, which led the court to provide partial relief to an injunction granted to Bayer, allowing Ajanti to manufacture but not sell the product, in January 2017.<ref name="Bayer vs Ajanta" /> Bayer and Ajanti reached an unspecified agreement after mediation was ordered by the court in February 2017.<ref name="Bayer vs Ajanta" />
[[Bayer]]<ref group="nt">Specifically Bayer Intellectual Property GMBH</ref> filed suit before the [[Delhi High Court]] accusing Ajanta of [[patent infringement]] on the [[erectile dysfunction]] treatments [[vardenafil]] and [[vardenafil hydrochloride]].<ref name="Bayer vs Ajanta" /> Ajanta argued that Bayer was not using its patent in India for the benefit of India, which led the court to provide partial relief to an injunction granted to Bayer, allowing Ajanta to manufacture but not sell the product, in January 2017.<ref name="Bayer vs Ajanta" /> [[Bayer]] and Ajanta reached an unspecified agreement after mediation was ordered by the court in February 2017.<ref name="Bayer vs Ajanta" />


==References==
==References==
{{reflist |refs=
{{reflist |33em |refs=
<ref name="Accounting and Analysis 2006">{{Cite book|url=https://books.google.com/books?id=Cbcf3dEKhh4C&newbks=1&newbks_redir=0&lpg=PA493&dq=Ajanta%20Pharma%20Limited&pg=PA153#v=onepage&q=Ajanta%20Pharma%20Limited&f=false|title=Accounting & Analysis: The Indian Experience|last=|first=|publisher=Global Data Services of India (CRISIL)|year=2006<!--from cover image-->|isbn=9788190342704|edition=Professional|location=|pages=153|chapter=Investments|via=Google Books (Preview)}}</ref>
<ref name="Accounting and Analysis 2006">{{Cite book|chapter-url=https://books.google.com/books?id=Cbcf3dEKhh4C&q=Ajanta+Pharma+Limited&pg=PA153|title=Accounting & Analysis: The Indian Experience|publisher=Global Data Services of India (CRISIL)|year=2006<!--from cover image-->|isbn=9788190342704|edition=Professional|pages=153|chapter=Investments|via=Google Books (Preview)}}</ref>


<ref name="Bayer vs Ajanta">{{Cite book|url=https://books.google.com/books?id=D4GHEo9HZOYC|title=International Pharmaceutical Law and Practice|last=|first=|publisher=LexisNexis|year=2019|isbn=9781579114725|editor-last=Kleyn|editor-first=Madelein|location=|pages=§14.09[11]|editor-last2=van Wyk|editor-first2=Louis|via=Google Books (Preview)}}</ref>
<ref name="Bayer vs Ajanta">{{Cite book|url=https://books.google.com/books?id=D4GHEo9HZOYC|title=International Pharmaceutical Law and Practice|publisher=LexisNexis|year=2019|isbn=9781579114725|editor-last=Kleyn|editor-first=Madelein|pages=§14.09[11]|editor-last2=van Wyk|editor-first2=Louis|via=Google Books (Preview)}}</ref>


<ref name="Lal 2006">{{Cite book|url=https://books.google.com/books?id=Fyi1JFWUvngC&newbks=1&newbks_redir=0&lpg=PR17&dq=Ajanta%20Pharma%20Limited&pg=PA32#v=onepage&q=Ajanta%20Pharma%20Limited&f=false|title=Central Asia and Its Asian Neighbors: Security and Commerce at the Crossroads|last=Lal|first=Rollie|publisher=Project Air Force (Rand)|year=2006|isbn=0-8330-3878-8|location=United States|pages=32&ndash;3|via=Google Books (Preview)}}</ref>
<ref name="Lal 2006">{{Cite book|url=https://books.google.com/books?id=Fyi1JFWUvngC&q=Ajanta+Pharma+Limited&pg=PA32|title=Central Asia and Its Asian Neighbors: Security and Commerce at the Crossroads|last=Lal|first=Rollie|publisher=Project Air Force (Rand)|year=2006|isbn=0-8330-3878-8|location=United States|pages=32&ndash;3|via=Google Books (Preview)}}</ref>


<ref name="Thukral 2016">{{Cite book|url=https://books.google.com/books?id=csMyDwAAQBAJ&newbks=1&newbks_redir=0&lpg=PA85&dq=Ajanta%20Pharma%20Limited&pg=PA85#v=onepage&q=Ajanta%20Pharma%20Limited&f=false|title=India Top 10 Year Book 2016|last=|first=|publisher=Publication Cell (Datanet India)|year=2016|isbn=978-93-80590-60-8|editor-last=Thukral|editor-first=R. K.|location=New Delhi, India|pages=85|via=Google Books (Preview)}}</ref>
<ref name="Thukral 2016">{{Cite book|url=https://books.google.com/books?id=csMyDwAAQBAJ&q=Ajanta+Pharma+Limited&pg=PA85|title=India Top 10 Year Book 2016|publisher=Publication Cell (Datanet India)|year=2016|isbn=978-93-80590-60-8|editor-last=Thukral|editor-first=R. K.|location=New Delhi, India|pages=85|via=Google Books (Preview)}}</ref>
}}
}}


== Notes ==
== Notes ==
{{Reflist|group=nt}}
{{Reflist|group=nt}}

== Further reading ==


=== Patent applications in India ===
=== Patent applications in India ===


* 1999—[[iarchive:in.gazette.1999.192/page/n3|Gazette of India, 18 September 1999, p. 843]]; [[iarchive:in.gazette.central.w.2000-02-26.203/page/n5|Gazette of India, 26 February 2000, p. 116]]; [[iarchive:in.gazette.central.w.2000-03-04.200/page/n4|Gazette of India, 4 March 2000, p. 123]]; [[iarchive:in.gazette.2001.466/page/n21|Gazette of India, 20 October 2001, p. 1886]]
* 1998—[[iarchive:in.gazette.central.w.1998-10-31.5368/page/n10|Gazette of India, 31 October 1998, p. 1087]]; [[iarchive:in.gazette.central.w.2000-02-26.203/page/n5|Gazette of India, 26 February 2000, p. 116]]
*1999—[[iarchive:in.gazette.1999.192/page/n3|Gazette of India, 18 September 1999, p. 843]]; [[iarchive:in.gazette.central.w.2000-03-04.200/page/n4|Gazette of India, 4 March 2000, p. 123]]; [[iarchive:in.gazette.2001.466/page/n21|Gazette of India, 20 October 2001, p. 1886]]
* 2000—[[iarchive:in.gazette.2000.157/page/n11|Gazette of India, 24 June 2000, p. 477]]; [[iarchive:in.gazette.2001.245/page/n11|Gazette of India, 30 June 2001, p. 867]]; [[iarchive:in.gazette.2000.174/page/n1|Gazette of India, 14 October 2001, p. 975]]; [[iarchive:in.gazette.2002.161/page/n53|Gazette of India, 8 June 2002, p. 1178]]; [[iarchive:in.gazette.2003.496/page/n159|Gazette of India, 6 September 2003, p. 4006]]
* 2000—[[iarchive:in.gazette.2000.157/page/n11|Gazette of India, 24 June 2000, p. 477]]; [[iarchive:in.gazette.2001.245/page/n11|Gazette of India, 30 June 2001, p. 867]]; [[iarchive:in.gazette.2000.174/page/n1|Gazette of India, 14 October 2001, p. 975]]; [[iarchive:in.gazette.2002.161/page/n53|Gazette of India, 8 June 2002, p. 1178]]; [[iarchive:in.gazette.2003.496/page/n159|Gazette of India, 6 September 2003, p. 4006]]
*2001—[[iarchive:in.gazette.2003.478/page/n83|Gazette of India, 29 March 2003, p. 1200]]
*2001—[[iarchive:in.gazette.2003.478/page/n83|Gazette of India, 29 March 2003, p. 1200]]
Line 89: Line 95:
*[http://forbesindia.com/article/super-50-companies-2015/ajanta-pharma-the-small-big-dream/40691/1 Ajanta Pharma Ltd Listed in 'Forbes India - Super 50 Companies']
*[http://forbesindia.com/article/super-50-companies-2015/ajanta-pharma-the-small-big-dream/40691/1 Ajanta Pharma Ltd Listed in 'Forbes India - Super 50 Companies']
*[http://www.indiainfoline.com/Markets/Company/Background/Company-Profile/Ajanta-Pharma-Ltd/532331 Ajanta Pharma Ltd |Company Profile]
*[http://www.indiainfoline.com/Markets/Company/Background/Company-Profile/Ajanta-Pharma-Ltd/532331 Ajanta Pharma Ltd |Company Profile]

{{Nifty 200 companies}}


[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies of India]]
[[Category:Companies based in Mumbai]]
[[Category:Manufacturing companies based in Mumbai]]
[[Category:Indian companies established in 1973]]
[[Category:1973 establishments in Maharashtra]]
[[Category:Pharmaceutical companies established in 1973]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]

Latest revision as of 04:00, 26 September 2024

Ajanta Pharma Limited
Company typePublic Company
IndustryPharmaceuticals, Drugs & Healthcare
Founded1973, 51 years
Headquarters
Mumbai, Maharashtra[1]
,
India
Key people
Yogesh Agrawal, Managing Director. Rajesh Agrawal, Joint Managing Director
ProductsBranded Generic Formulations / Medicines
RevenueIncrease ₹2,916 crore (US$350 million) (2020–2021)
Number of employees
7,000+
Subsidiaries
  • Ajanta Pharma (Mauritius) Ltd
  • Ajanta Pharma Philippines Inc.
  • Ajanta Pharma USA Inc.[2]
  • Ajanta Pharma Nigeria Ltd.[3]
Websitehttp://www.ajantapharma.com/
Footnotes / references
;[1][2][3]

Ajanta Pharma Limited, also known by the acronym APL, is a multinational company based in India engaged in development, manufacturing, and marketing of pharmaceutical formulations. It has a presence in India, the United States, and about 30 other countries in Africa, South East Asia, West Asia, and CIS. It was established in 1973.

Markets and business

[edit]

Ajanta Pharma has over 1,400 products registered currently in various countries and an equal number of products are under approval. In India, the company is a branded generic company focused on a few high growth specialty therapies in ophthalmology, dermatology, cardiology, and pain management.

Ajanta Pharma exports products to over 30 countries in Asia and Africa. In these markets, the company serves a wide range of therapeutic products in the areas of antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology, and pain management.

Ajanta Pharma has recently stepped up its presence in the United States with a select product portfolio, which includes niche and complex technology products. Currently, the company has 27 products in the US market.[4]

History

[edit]

In the early 2000s, Ajanta was noted as a major source of foreign currency, alongside Reddy Labs, arising from sales in Southeast Asia.[5] In particular, in 2003, a joint-venture between Ajanta and the Ministry of Health in Turkmenistan accounted for fully half of the pharmaceutical needs of the country.[5] The company had made several other joint-ventures with regional governments, such as Uzbekistan, Kazakhstan, Kyrygyzstan and Tajikistan, which it severed in the 2010s due to their being unprofitable.[6]

The company experienced an enormous loss in 2005[nt 1] in terms of diminution of the value of investments, amounting to four times the year's profits.[7] That same year, the company was noted as having the highest sales in India for any Indian pharmaceutical company, with sales of ₹13.56 billion.[8]

In 2015, the company was highlighted as having had exceptional stock appreciation over the preceding four years, and the listing of the stock on the BSE 500 was noted.[9] By 2019, the stock was listed on the S&P BSE 200 index.[10]

Manufacturing facilities

[edit]

Ajanta Pharma operates seven manufacturing facilities in India. Six facilities manufacture finished formulations, including Dahej and Paithan plants which is approved by the US FDA and Guwahati plant which caters to domestic and emerging markets. Another plant manufactures active pharmaceutical ingredients (APIs) primarily for captive consumption.

[edit]

Bayer[nt 2] filed suit before the Delhi High Court accusing Ajanta of patent infringement on the erectile dysfunction treatments vardenafil and vardenafil hydrochloride.[11] Ajanta argued that Bayer was not using its patent in India for the benefit of India, which led the court to provide partial relief to an injunction granted to Bayer, allowing Ajanta to manufacture but not sell the product, in January 2017.[11] Bayer and Ajanta reached an unspecified agreement after mediation was ordered by the court in February 2017.[11]

References

[edit]
  1. ^ a b "Welcome To Ajanta Pharma". Ajantapharma.com. Retrieved 29 February 2016.[self-published source]
  2. ^ a b "Stock Snippets". Daily Market Insights. TriFid Research. 15 June 2016. p. 2 – via Internet Archive. Ajanta Pharma announced the launch of anti-dementia Memantine Hydrochloride tablets in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc.
  3. ^ a b "Ajanta Pharma Limited - Our Business". Company. Retrieved 29 February 2016.[self-published source]
  4. ^ "Profit After Tax at 14% of Revenue (3rd Quarter & 9 Months, FY 2019 Consolidated Results)" (PDF) (Press release). Ajanta Pharma Limited. Archived from the original (PDF) on 27 September 2020.
  5. ^ a b Lal, Rollie (2006). Central Asia and Its Asian Neighbors: Security and Commerce at the Crossroads. United States: Project Air Force (Rand). pp. 32–3. ISBN 0-8330-3878-8 – via Google Books (Preview).
  6. ^ GOI Considering Russian Thrust in Central Asia (Partial extract from original diplomatic, classified cable). United States Department of State. 26 September 2015. p. 2. Retrieved 8 December 2019 – via Internet Archive.
  7. ^ "Investments". Accounting & Analysis: The Indian Experience (Professional ed.). Global Data Services of India (CRISIL). 2006. p. 153. ISBN 9788190342704 – via Google Books (Preview).
  8. ^ Thukral, R. K., ed. (2016). India Top 10 Year Book 2016. New Delhi, India: Publication Cell (Datanet India). p. 85. ISBN 978-93-80590-60-8 – via Google Books (Preview).
  9. ^ Oberoi, Rahul (April 2015). "Bullish Moves: We discuss three ratios that can help identify good stocks". Money Today. Vol. 10, no. 4. New Delhi, India: India Today Group. p. 49 – via Internet Archive.
  10. ^ "Ajanta Pharma Ltd Live Stock Price, Ajantpharm Live Share Price, 532331". BSE. 8 December 2019. Archived from the original on 9 December 2019. Retrieved 8 December 2019.
  11. ^ a b c Kleyn, Madelein; van Wyk, Louis, eds. (2019). International Pharmaceutical Law and Practice. LexisNexis. pp. §14.09[11]. ISBN 9781579114725 – via Google Books (Preview).

Notes

[edit]
  1. ^ Year ending 31 March 2005
  2. ^ Specifically Bayer Intellectual Property GMBH

Patent applications in India

[edit]

Products subject to price control in India

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Ajanta_Pharma&oldid=1247811706"